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Abstract
BACKGROUND: Circulating inflammatory markers may play an important role in cognitive impair-
ment at older ages. Mice deficient for the chemokine (C-C motif) receptor 2 (CCR2) develop an accelerated
Alzheimers-like pathology, and CCR2 is also important in neurogenesis. To identify human gene transcripts
most closely associated with Mini Mental State Examination (MMSE) scores we undertook a genome-wide
and inflammation specific transcriptome screen in circulating leukocytes from a population-based sample.
METHODS: We measured in-vivo transcript levels by microarray analysis in 691 subjects (mean age
72.6 yrs) in the InCHIANTI study. We assessed expression associations with MMSE performance at RNA
collection and prior 9 year change in MMSE score in linear regression models.
RESULTS: In genome-wide analysis, raised CCR2 expression was cross-sectionally the most strongly asso-
ciated transcript with lower MMSE score (beta=-0.16, p=5.1e-6, False discovery rate FDR q=0.077). Amongst
inflammatory transcripts, only CCR2 expression was associated with both MMSE score and accelerated de-
cline in score over the preceding 9 years (beta=-0.16, p=5.1e-6, q=0.003; and beta=-0.13, p=5.5e-5, q=0.03;
respectively). CCR2 expression was also positively associated with ApoE e4 Alzheimers disease risk haplotype.
CONCLUSIONS: We show for the first time that CCR2 expression is associated with lower MMSE
scores in an older human population. Laboratory models of Ccr2-mediated -amyloid removal and regulation
of neurogenesis affecting cognitive function may be applicable in humans. CCR2-mediated pathways may
provide a possible focus for intervention to potentiate protective reactions to Alzheimers pathology in older
people, including for people with adverse ApoE haplotype.
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1 Introduction
Cognitive impairment and dementia at older ages com-
monly results from accumulating vascular and neurode-
generative pathology in the brain 1 and is experienced
by over half of adults aged 85 or over 2. Major risk
factors for cognitive impairments in later life include
APOE e4 haplotype 3, but the underlying biological
mechanisms are still unclear. Gene expression arrays
offer a new approach to identifying the most impor-
tant molecular mechanisms causing or responding to the
pathologies underlying cognitive decline. The most ac-
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2 RESULTS
cessible tissue for gene expression array analyses in large
numbers of older people is circulating blood leucocytes,
which are likely to be most sensitive to inflammatory
and related mechanisms.
Chronic low-level inflammation has been proposed
as a key mechanism underlying cognitive decline and
dementia, and has been implicated in the neuropatho-
logical cascade leading to late onset Alzheimers disease
(LOAD) 4. Inflammatory factors have been further im-
plicated in cognitive impairment and dementia using
mouse models 5. These include transgenic animals in
which chemo-attractant proteins or receptors such as
Ccl2 or Ccr2 have been abolished 5. These genes, associ-
ated with the migration of phagocytic and inflammatory
macrophages, have been associated with Alzheimers
pathology and peripheral atherosclerosis 5-7. Ccr2-
deficient mice show early accumulation of β-amyloid,
with premature mortality 7. Blood-borne systemic fac-
tors including CCR2 and CCL11 were also recently im-
plicated in the negative regulation of neurogenesis and
cognitive function in rodent studies 8.
The importance of CCR2 and related signaling in
human age-related cognitive impairment is unclear.
Maes et al (2007) identified leukocyte expression dif-
ferences between 14 Alzheimers Disease and control in-
dividuals in a microarray experiment 9, while Grun-
blatt et al identified five peripheral blood leucocyte
genes whose mRNA correlated significantly with MMSE
(Mini Mental State Examination) score in a smaller se-
ries of Alzheimers and control individuals 10. These
studies present initial evidence that brain changes in
pathologically-specific dementia patients may be de-
tectable using peripheral leukocyte gene expression, but
it is currently not known if this also applies to age-
associated cognitive decline.
In the current study, we used a genome-wide and
inflammation-focused approach to identify the most
strongly associated in-vivo transcript levels in circulat-
ing leukocytes associated with MMSE score or rate of
change in MMSE score in a general population sample
of predominantly older people. The MMSE is a widely
used measure of cognitive function in prospective epi-
demiological studies of elderly populations, and is sensi-
tive to moderate or severe cognitive declines, often due
to dementia 11,12. To ensure population relevance, no
exclusions for co-morbidity were made in the main anal-
ysis.
2 Results
2.1 Cohort Details
Participant characteristics are given in table 1; the
study sample had a mean age of 72.6 years (SD: 15.3,
range 30 to 104) and 55.2% were female. At RNA col-
lection the mean MMSE score was 25.58 (SD 5.66), 21%
of the sample had MMSE scores of 23 or less (8.1% with
MMSE of 18 or less), and the mean change in MMSE
scores over 9 years was -1.31 (SD = 4.71).
Table 1: This table summarises the population statis-
tics for the 691 participants eligible for our study
Summary Statistics
Age (years) n
30-49 86 (12.5%)
50-69 98 (14.2%)
70-89 479 (69.3%)
90-104 28 (4%)
Mean age at RNA-collection 72.6 (SD: 15.3)
Gender %
Men 44.8
Women 55.2
MMSE Score
Mean score at RNA-collection 25.58 (SD: 5.66)
Mean change in MMSE (9 years) -1.31 (SD: 4.71)
Frequency of scores (year 9) %
0-18 8.14
19-23 12.79
24-27 30.52
28-30 48.55
Education %
None 13.31
Elementary 46.02
Secondary 13.46
High school 12.59
University / Professional 14.62
Pack years smoked (lifetime) %
None 55.72
0.1-20 22.87
20-39 14.33
40+ 7.09
2.2 Genome wide analysis
In genome wide analysis, only one transcript (CCR2,
measured via probe ilmn 1774761) showed a very near
significant genome wide association with MMSE score
at RNA collection (beta=-0.16, p=5.1e-6; q=0.076; ta-
ble 2). No probes were significantly associated (q <0.1)
with change in MMSE score over the preceding 9 years
(table 2), although CCR2 was the most strongly asso-
ciated transcript (beta=-0.13, p=5.5e-5, q=0.70).
Quantile-Quantile (QQ) plots comparing the ob-
served p-values (-log10) with those that would be ex-
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Table 2: The ten probes most closely associated with MMSE score at wave 9 and change in MMSE score
(baseline to year 9), ordered by false discovery rate q-value (n observations = 688)
Probe ID p-value Coefficient Beta 95% CIs q-value Gene
MMSE score at year 9
ilmn 1774761 5.1e-6 -0.0042 -0.1616 -0.0056 -0.0027 0.076 CCR2
ilmn 2374362 2.7e-5 -0.0015 -0.1709 -0.0021 -0.0009 0.204 FAM108B1
ilmn 1791912 1.1e-4 0.0052 0.1475 0.0030 0.0074 0.356 SIDT2
ilmn 1758457 1.2e-4 0.0008 0.1473 0.0005 0.0011 0.361 TBC1D16
ilmn 1796094 1.5e-4 -0.0044 -0.1486 -0.0063 -0.0025 0.381 CD36
ilmn 1693949 1.7e-4 0.0011 0.1153 0.0006 0.0015 0.390 UNQ1944
ilmn 1724266 2.8e-4 0.0017 0.1382 0.0009 0.0025 0.418 LYPD2
ilmn 1772821 3.7e-4 -0.0015 -0.1561 -0.0022 -0.0008 0.430 KIAA1671
ilmn 2313434 3.9e-4 0.0013 0.1476 0.0007 0.0019 0.433 TCP1
ilmn 2393573 4.1e-4 -0.0019 -0.1073 -0.0027 -0.0010 0.434 RASSF1
Change in MMSE score (9 years)
ilmn 1774761 5.5e-5 -0.0040 -0.1305 -0.0056 -0.0024 0.700 CCR2
ilmn 2374362 1.5e-4 -0.0015 -0.1345 -0.0022 -0.0009 0.700 FAM108B1
ilmn 1796094 2.2e-4 -0.0047 -0.1146 -0.0067 -0.0026 0.700 CD36
ilmn 1761941 2.6e-4 -0.0017 -0.1135 -0.0024 -0.0009 0.700 C4orf18
ilmn 2313434 2.7e-4 0.0015 0.1273 0.0008 0.0022 0.700 TCP1
ilmn 1712684 3.1e-4 -0.0011 -0.1245 -0.0015 -0.0006 0.700 FAM20C
ilmn 1866887 3.4e-4 -0.0011 -0.1290 -0.0016 -0.0006 0.700 BX537605
ilmn 1772821 5.6e-4 -0.0016 -0.1277 -0.0023 -0.0008 0.700 KIAA1671
ilmn 1703314 5.7e-4 0.0013 0.1167 0.0007 0.0020 0.700 KLHL36
ilmn 1789751 6.1e-4 -0.0039 -0.0985 -0.0058 -0.0020 0.700 MFSD1
pected by chance alone (figure 1a) confirmed that large
scale disruption to gene expression levels was not a fea-
ture of MMSE score at RNA collection or change in
score over the previous nine years, although some small
deviations from the expected pattern were noted.
2.3 Specific inflammatory analysis
In a targeted analysis on inflammation-related tran-
scripts only, the CCR2 transcript was associated with
MMSE score at RNA collection (beta=-0.16, p=5.1e-6,
q=0.003; table 3) and also with cognitive decline score
over the previous nine years, using a false-discovery rate
(FDR) of q<0.1 (beta=-0.13, p=5.5e-5, q=0.03; table
3). As in the genome wide analysis, other large-scale al-
terations in the expression of inflammatory genes were
not present (after accounting for multiple testing) for
either cognitive function or decline, although one large
effect (CCR2) was evident on the QQ plot (figure 1b).
2.4 The relationship between CCR2
and MMSE
To understand any non-linearity in the relationship be-
tween CCR2 expression and MMSE (and change in
MMSE over 9 years, delta-MMSE) we fitted a penalized
cubic spline regression model for; A. CCR2 expression
and MMSE at RNA collection, and B. CCR2 expres-
sion and delta-MMSE over the preceding nine years (see
figure 3 for spline regression plots). We found the re-
lationships to be approximately linear throughout the
MMSE or delta-MMSE ranges.
2.5 Quantitative real-time PCR valida-
tion of CCR2 levels
To validate our microarray results, we also quantified
CCR2 expression in a subset of our cohort using quan-
titative real-time PCR (QRT-PCR). We found that the
expression level of CCR2 transcripts as measured by
QRT-PCR correlated well with the expression levels
measured by microarray analysis (r2 = 0.5, p=2e-4).
2.6 Gene set enrichment analysis
No gene sets showed evidence of deregulation in associ-
ation with MMSE score at RNA collection or change in
score using GSEA (Gene Set Enrichment Analysis), at
a FDR q-value of <0.1 (table 4).
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Figure 1: Quantile-Quantile plots for gene expres-
sion analysis of MMSE score at RNA collection
— A. The Quantile-Quantile plot for the genome wide
analysis (16 571 transcripts) of MMSE at RNA collec-
tion is shown. The actual P-values (-log10) obtained are
given on the y-axis, plotted against expected P-values
(-log10) given on the X-axis. This graph shows poten-
tial deviations to the p-value distribution that might be
expected by chance. B. The Quantile-Quantile plot for
the focused analysis of inflammatory genes (635 tran-
scripts) is shown. The actual P-values (-log10) obtained
are given on the y-axis, plotted against expected P-
values (-log10) given on the X-axis. This graph shows
potential deviations to the p-value distribution that
might be expected by chance. The positive association
with the CCR2 transcript is circled.
2.7 Post-hoc Sensitivity analyses
To determine if the observed association is dependent
on the inclusion of some younger people in the predomi-
nantly older sample, or dependent on the oldest old, we
carried out a sensitivity analysis in subjects aged =70
and <90 years old at RNA-extraction; MMSE score and
(logged) CCR2 expression were still strongly associated
(beta=-0.15, p = 2e-4) within this age-range. ApoE
genotype was available on n=480 (excluding e2e4 n=4)
in our sample: CCR2 expression was positively associ-
ated with ApoE risk haplotype (trend test across e2e2,
e2e3, e3e3, e3e4, e4e4 groups: coef=0.02, CIs: 0.007
to 0.03, p=0.001). The association between CCR2 ex-
pression and MMSE at RNA collection was attenuated
but remained significant after additional adjustment for
ApoE status (beta = -0.1, p = 0.018). There was no
statistical interaction between ApoE status and CCR2
expression.
Co-morbidity is very common with cognitive impair-
ment in later life in the general older population, and
therefore our approach has been to avoid disease specific
exclusions: however, we did examine the effect of remov-
ing those diagnosed as having had a stroke (n=76 re-
moved): CCR2 remained associated with MMSE score
(beta = -0.14, p=0.001) in the stroke free group.
Figure 2: Boxplot of CCR2 expression by MMSE
score at RNA collection— The boxplot shows CCR2
transcript expression levels (relative units) as plotted on
the Y-axis by MMSE score RNA collection on the X-
axis.
3 Discussion
In this study, we have investigated associations be-
tween blood leukocyte-derived mRNA expression and
MMSE scores in an ageing population. CCR2 ex-
pression reached inflammation-specific significance (and
only narrowly missed genome wide significance after ac-
counting for multiple testing), providing the first human
population evidence of likely consistency with the Ccr2
mouse models.
Our finding that ApoE haplotype status, the major
inherited genetic risk factor associated with Alzheimers
pathology, is associated with CCR2 expression is also
consistent with CCR2 signaling having a direct role in
cognitive decline in later life in human populations.
The MMSE score is a widely used measure of cog-
nitive impairment in later life, although it has a ceiling
effect that limits its ability to detect early subtle cogni-
tive changes, particularly in younger highly educated
participants 11,13 and is not considered an appropri-
ate measure to diagnose mild cognitive impairment or
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Table 3: The ten inflammation-related probes most closely associated with MMSE score at wave 9 and change
in MMSE score (baseline to year 9), ordered by false discovery rate q-value (n observations = 688)
Probe ID p-value Coefficient Beta 95% CIs q-value Gene
MMSE score at year 9
ilmn 1774761 5.1e-06 -0.0042 -0.1616 -0.0056 -0.0027 0.003 CCR2
ilmn 2366212 1.5e-03 0.0083 0.1267 0.0040 0.0125 0.232 CD79B
ilmn 1677440 2.6e-03 -0.0055 -0.1194 -0.0084 -0.0025 0.262 ATP6AP2
ilmn 2276996 2.8e-03 -0.0009 -0.1071 -0.0014 -0.0004 0.266 CCR2
ilmn 1785439 3.9e-03 0.0042 0.1239 0.0018 0.0066 0.279 CD79B
ilmn 1710017 3.9e-03 0.0045 0.1302 0.0019 0.0070 0.279 CD79B
ilmn 1764396 5.3e-03 -0.0011 -0.0725 -0.0017 -0.0004 0.288 HDAC4
ilmn 1763875 6.1e-03 0.0022 0.0842 0.0009 0.0035 0.291 ABCF1
ilmn 1738767 6.5e-03 -0.0012 -0.0780 -0.0019 -0.0005 0.293 PLP2
ilmn 1747227 7.1e-03 0.0008 0.1412 0.0003 0.0013 0.295 ADORA1
Change in MMSE score (9 years)
ilmn 1774761 5.5e-05 -0.0040 -0.1305 -0.0056 -0.0024 0.033 CCR2
ilmn 2366212 2.1e-03 0.0087 0.1047 0.0041 0.0134 0.305 CD79B
ilmn 1710017 2.2e-03 0.0052 0.1013 0.0024 0.0079 0.310 CD79B
ilmn 1677440 2.9e-03 -0.0059 -0.0946 -0.0091 -0.0027 0.325 ATP6AP2
ilmn 1747227 3.2e-03 0.0009 0.1169 0.0004 0.0015 0.332 ADORA1
ilmn 1737398 3.3e-03 -0.0012 -0.0938 -0.0018 -0.0005 0.332 PTPLAD1
ilmn 1785439 4.1e-03 0.0046 0.1024 0.0020 0.0072 0.349 CD79B
ilmn 1682312 6.5e-03 -0.0025 -0.0726 -0.0040 -0.0010 0.377 CYBB
ilmn 1811049 6.8e-03 0.0012 0.0999 0.0005 0.0019 0.379 POU2AF1
ilmn 1771333 6.9e-03 -0.0035 -0.0877 -0.0057 -0.0014 0.380 CD47
related prodromal diagnoses without supplementing it
with other cognitive measures, although the population
relevance of these clinically-derived constructs remains
disputed 14. Over several years follow-up the MMSE
does however provide a useful measure of cognitive im-
pairment and cognitive decline in participants with and
without dementia 12, and is the most widely used mea-
sure to monitor cognitive function and decline in elderly
adults in clinical settings. We therefore consider that it
is an appropriate tool to assess age-related differences
in cognitive function in our cross sectional population.
Our functional, rather than pathological, classifica-
tion of participants was important for several reasons.
Cognitive decline leads to impairments in activities of
daily living, and is a major public health threat. It is
also rarely determined purely by one pathophysiologi-
cal mechanism - mixed dementia is now considered to
be the most common form of dementia 15 and func-
tional decline has only a moderate association with the
pathological changes of Alzheimer disease 16. Finally,
our use of a large, population-based cohort, rather than
from specialist clinics, gave us power to detect moder-
ate biomarker effects that could be of clinical applica-
tion in population testing and risk reduction: biomark-
ers of functional cognitive change may hold more clini-
cal application in the population than markers of single
pathological processes.
We investigated blood leukocytes in order to iden-
tify clinically useful, minimally invasive markers of cog-
nitive function since cortical tissue is inappropriate for
the identification of cognitive decline risk or progression
in the population. Furthermore, recent studies suggest
that circulating systemic factors such as chemokines and
their receptors have an important role in neurogenesis
and cognitive function in animal models 8. Peripheral
inflammation has also been shown to impact negatively
on human cognitive function 17 with chronic immune
activation in the brain having an association with neu-
rodegenerative disease and cognitive decline 18,19.
There are both similarities and differences between
our data and previous studies 9,10,20,21. It has been sug-
gested that genes involved in cytoskeletal maintenance,
cellular trafficking, cellular stress response, redox home-
ostasis, transcription and DNA repair may be associ-
ated with Alzheimers Disease 14 and proteomics stud-
ies have suggested that circulating lymphocytes may be
promising biomarkers for this disorder 25. The differ-
ences could arise from different patient selection criteria;
we used population data rather than data from clinical
settings.
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Figure 3: Cubic Spline plots for linearity of as-
sociation between CCR2 expression and MMSE
— A. CCR2 expression and MMSE at RNA collec-
tion. B. CCR2 expression and delta-MMSE over the
preceding nine years. These penalized cubic regression
splines visualize the fitted (adjusted) relationship be-
tween CCR2 gene expression and MMSE score, and
separately with change in MMSE over 9 years. The
relationships are approximately linear after normaliza-
tion (log-transformed expression data) and adjustment
for multiple confounders
Differences with prior proteomic findings in periph-
eral blood in cognitive decline 22,23 may also be due to
small study sizes or the possibility that circulating cy-
tokines previously found associated with cognitive de-
cline may be expressed by activated CNS inflammatory
cells and released into the circulation, rather than being
expressed by circulating leukocytes 24.
The CCR2 receptor binds CCL2, a protein that
is abundantly expressed in macrophage-rich areas of
atherosclerotic plaques and in brain microglia 7 re-
sulting in migration of macrophages and brain mi-
croglial cells to their site of action. In mouse mod-
els, vascular disruption of Ccr2 or Ccl2 leads to
a reduction in atherosclerotic plaque formation in
ApoE- or LDL-R null mice, even when fed a high
fat diet 6,25. This may be mediated by Ccr2 de-
pletion reducing macrophage infiltration. In mouse
brain, Ccr2 knockout has been shown to result in ac-
celerated disease progression, increased mortality and
an increase in soluble Aβ assemblies 7,26. Work on
CCR2 gene knockout mice bred on a background of
chimeric mouse/human β-amyloid precursor/presenilin
over-expression (APPSwe/PS1/CCR2-/-) suggested that
AD might be associated with a decreased expression of
CCR2 26. Although our results at first appear to con-
flict with this, we suggest that the increased CCR2 lev-
els we note in cognitively impaired individuals probably
reflects a reactive increase in the need for chemoattrac-
tants in subjects with increased β-amyloid deposition.
This is supported by the observation that the ligand for
CCR2, CCL2, has previously been reported to be up-
regulated in the brain of patients suffering from AD 27.
Recent studies have also suggested that CCR2 is with
a key modulator of negative regulation of neurogenesis
and cognitive function in mice 8. Our data supports
a role for CCR2 in the aetiology of age-related cogni-
tive decline, and indicates that the CCR2 mouse models
7,26 may have particular relevance to the human popu-
lation, although much more work is needed to confirm
this mechanism in human populations.
Key limitations of our study include the possibility
that that there are gene expression correlates of cogni-
tive function in specific white cell subtypes which we
have not measured separately. These are not however
likely to be very marked or common, as we have found
only limited overall expression changes. Similarly, as
noted above the MMSE score, a widely used clinical
measure of cognitive function in older people, suffers
from a relative insensitivity to frontal-executive dys-
function and visuo-spatial deficits 28, and a ceiling effect
inhibiting sensitive differentiation between medium and
high cognitive performers 29. Our cohort may also be
subject to informative loss to follow up, and reflect a
higher functioning group, since people with very im-
paired cognitive function may not have reported for
blood sampling in year 9.
We note also that several probes to CCR2 tran-
scripts were present on the chip, but only one showed
associations with MMSE score. Differences in the re-
lationship between phenotype and alternative specific
probes for the same gene are not atypical in microarray
studies. These discrepancies can arise from several fac-
tors including differences in binding dynamic of the indi-
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Table 4: Biological and molecular functional pathway enrichments for negative correlation with MMSE are
presented
Pathway Size ES p-value q-value
Aromatic compound metabolic process 17 -1.82 0 0.85
Regulation of DNA metabolic process 29 -1.74 0.008 0.95
T cell activation 27 -1.56 0.031 1
Transferase activity transferring glycosyl groups 68 -1.42 0.034 1
Cellular defense response 38 -1.52 0.035 1
Anatomical structure formation 27 -1.55 0.036 1
Positive regulation of lymphocyte activation 15 -1.58 0.039 1
Coenzyme metabolic process 30 -1.44 0.045 1
RNA export from nucleus 17 -1.52 0.045 1
DNA recombination 32 -1.5 0.047 1
vidual probes, differences in the inter-individual inten-
sities between probe signal which can add noise to the
data and reduce power and the presence of alternatively-
processed isoforms which may bind probes differentially.
In the case of CCR2, three alternatively-expressed iso-
forms exist, with only a single probe, ilmn 1774761, ca-
pable of binding to all isoforms. If the effect we note
is driven by a specific isoform, only those probes that
identify the transcript in question will show a significant
association. Since up to 90% of all genes are alterna-
tively spliced, and the full transcriptomic output from
any gene is not fully known at present, this can lead
to apparent differences in the association of particular
probes with disease phenotype in association studies.
Future work should first seek to replicate our CCR2
finding, and explore associations with the full range
of isoform specific probes for the main target genes.
Work should also seek to gather more evidence on which
of the near significant probes may in fact be associ-
ated with cognitive function. Future prospective studies
will also provide valuable information as to the role of
chemo-attractant proteins in age-related cognitive de-
cline. Functional work in humans is also needed to
clarify the mechanisms involved in the raised expression
of CCR2 we observed in those with lower or declining
MMSE scores. Studies of the role of CCR2 in specific
forms of dementia (Alzheimers, vascular, Lewy Body
etc, or mixed) would also help characterise the role of
CCR2. If raised expression of CCR2 is a helpful but
insufficient response to the accumulation of -amyloid,
then attempts to increase this response further may po-
tentially be effective. Studies of the role of CCR2 in
vascular disease and pro-inflammatory response would
also be informative. Our findings raise the possibility
that CCR2 expression levels may also be associated with
early, pre-symptomatic cognitive changes, although a
more sensitive approach than change in MMSE score
would be required to detect this.
To conclude, we have carried out the largest assess-
ment of in-vivo leukocyte human gene expression al-
terations in conjunction with MMSE measured cogni-
tive function in a predominantly older population, to
date. We identified associations between MMSE score
and CCR2 transcript levels, which may reflect the key
role CCR2 plays in the removal of -amyloid and in reg-
ulation of neurogenesis. Work is now needed to con-
firm our findings, establish whether these reflect the
proposed mechanisms and relate the circulating tran-
scriptome changes to specific forms of brain pathology.
4 Material and Methods
4.1 Study cohort
We used InCHIANTI, a population-based study of aging
30, which has followed older persons over a 9 year pe-
riod to assess normal aging using both interviews (con-
ducted at the participants home by experienced inter-
viewers) and blood samples (in the study clinic, all pa-
tients fasted for 8 hours prior to collection). Periph-
eral blood samples for RNA extraction were collected
from participants at the 9 year follow-up (2008/9). Co-
hort demographics are given in table 1. Ethical ap-
proval was granted by the Instituto Nazionale Riposo e
Cura Anziani institutional review board in Italy. Par-
ticipants gave written informed consent to participate
and for sample collection after having received an ex-
tensive description of the procedures, purposes and po-
tential risks of the study. RNA was extracted from each
sample using the PAXgene Blood mRNA kit (Qiagen,
Crawley, UK) according to the manufacturers instruc-
tions. To ensure population relevance, no exclusions for
co-morbidity were made in the main analysis.
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4.2 Whole transcriptome scan
Whole genome expression profiling of the samples was
conducted using the Illumina Human HT-12 microar-
ray (Illumina, San Diego, USA), data processing was
carried out using the Illumina and Beadstudio software
(Illumina, San Diego, USA) as previously described
31. Baseline intensities were calculated as mean and
SD computed over all beads for a particular probe.
QC steps included correction for local background ef-
fects, removal of outlier beads, computation of aver-
age bead signal and SD for each probe and gene, cal-
culation of detection p-values using negative controls
present on the array, quantile normalization across ar-
rays, check of outlier samples using a clustering algo-
rithm, and checks of positive controls. Subject level QC
steps included removing individuals where the expres-
sion intensity was +/- 3 standard deviations from the
mean. All microarray experiments and analyses com-
plied with MIAME guidelines 32. Following microarray
data QC steps, 16,571 transcripts gave reliable signals
above background (p<0.01) in >5% of the sample pop-
ulation and were therefore eligible for analysis.
4.3 Cognitive assessment
Participant interviews and clinical assessment, includ-
ing the Mini-Mental State Examination of global cog-
nitive function (MMSE), were undertaken at baseline,
and at years 3, 6 and 9 of follow-up. The MMSE is
an assessment of global cognitive function widely used
in both hospital and community settings as a dementia
screening tool 33,34.
4.4 Sample and statistical analysis
From 733 blood samples collected, RNA quality and
microarray QC steps resulted in loss of 35 participants
from the analysis. From the remaining 698 participants,
7 were excluded due to absence of MMSE data, yielding
691 individuals. Three further individuals were dropped
from the regression models due to incomplete leukocyte
data. (See table 1 for summary statistics of the cohort
included in the analyses). All the remaining 688 in-
dividuals were included in the analyses, irrespective of
other pathologies.
Associations between gene expression and MMSE
score at RNA collection were analysed using multiple re-
gression models adjusted for the following potential con-
founding factors: age in years (as a continuous variable),
gender, highest level of education received (in five cat-
egories: none, elementary, secondary, high school, and
university/professional), lifetime pack-years smoked (in
four categories: none, 0.1 to 20 years, 20 to 39 years, and
40 plus years), blood leukocyte type (neutrophil, lym-
phocyte, monocyte, eosinophil percentages) each as con-
tinuous variables, hybridisation and amplification batch
(in 10 and 14 categories respectively), and study site;
participants lived in either a rural village (Greve) or an
urban site (Bagno a Ripoli).
Separate linear regression models were fitted for each
of the full set of 16,571 probes which passed QC in the
discovery dataset. We have expressed the effect sizes of
the associations in standardized betas to aid in the in-
terpretation (expression intensities vary from probe to
probe, and the normalization procedures further affect
the interpretability of coefficients). We controlled for
the effect of multiple testing by measuring the statistical
significance of each association using both the p-value
and the q-value. The q-value quantifies significance in
terms of the false discovery rate rather than the false
positive rate 35, and forms a measure of how likely a
particular p-value is to represent a genuine association.
Expression levels were taken to have a significant associ-
ation with MMSE score at RNA collection, or cognitive
decline from baseline 9 years previously, if the associ-
ation achieved a nominal p-value =0.05 and a q-value
<0.1. Our study was powered to detect expression dif-
ferences of <0.25 SD for the 16,571 transcripts studied,
allowing us to detect moderate expression differences
between groups.
4.5 Inflammatory gene scan
The large number of transcripts tested in the whole
genome scan yields a very stringent requirement
for statistical significance, resulting in a substantial
risk of type II (false negative) error. Since leuko-
cytes are an inflammation-related tissue, we carried
out a sub-analysis focusing on a smaller subset of
genes involved in inflammatory response only. The
genes of interest were identified using the Molecu-
lar Signatures Database (MSigDb) 36, with search
terms for inflammatory/immune-related gene path-
ways as defined by the Gene Ontology (GO) project
(www.geneontology.org). 44 inflammation-related gene-
sets were returned, comprising 635 unique probe IDs,
which equate to 425 unique genes with available data in
our cohort (Supplementary table 1). Linear regression
models were carried out as described above. This study
is powered to detect expression differences of <0.22 SD
for the inflammation transcript set.
4.6 PCR validation
The expression of the CCR2 gene in a subcohort of 100
individuals selected at the extremes of the MMSE spec-
trum was validated by the use of a custom real-time
PCR assay (probe and primer sequences available on
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request). Reaction mixes included 5 µl 2x TaqMan uni-
versal master mix (no AMPerase) (Applied Biosystems,
Foster City, USA), 30 µl dH2O and 2µl cDNA template.
PCR amplifications were performed on the ABI 7900HT
platform (Applied Biosystems, Foster City, USA). Cy-
cling conditions were 50◦C for 2 minutes, 94.5◦C for 10
minutes followed by 40 cycles of 97◦C for 30 seconds and
57.9◦C for 1 minute. The expression of each gene was
measured in triplicate for each sample. Gene expres-
sion relative changes were quantified using the 2-δδCt
method 37 relative to the geometric mean of the GUSB,
B2M and PPIA endogenous controls. The correlation
between quantifications achieved using microarray and
by real-time PCR was then assessed using linear regres-
sion.
4.7 Pathway Analysis
We also performed GSEA to identify gene
sets/pathways associated with cognitive function,
according to the method of Subramanian et al
36. Molecular or biological function pathways
were identified using Gene Ontology gene sets
from the molecular signature database (MSigDB)
(http://www.broadinstitute.org/gsea/msigdb/index.jsp).
Gene set size filtering excluded gene sets containing less
than 15 or more than 500 genes. Genes were ranked
according to the magnitude of their association with
cognitive function, and representation of each gene set
within this ranked list was analysed. Gene sets sig-
nificantly overrepresented at the top or bottom of the
ranked list were taken to be significantly associated
with cognitive function. A signal-to-noise metric was
used to rank genes, and gene set enrichment scores
were calculated using a weighted enrichment statistic.
One thousand random permutations of the phenotype
label were used to calculate the empirical p-values of
each pathway compared to the p-values that would be
ascertained by chance. Gene sets with a nominal p-
value<0.01 and q-value<0.1 were considered associated
with cognitive impairment or cognitive decline.
4.8 Spline regression
Using R package mgcv 38 we fitted an adjusted gener-
alized additive model (GAM) using a smoothed penal-
ized cubic regression spline; the smoothing parameter
was chosen automatically by cross-validation. The same
data and covariates that made up the original general-
ized linear regression (GLM) screen were used. GAM is
applied here because it allows non-parametric fits, and
thus if an aberrant relationship between expression and
age had existed it could be highlighted.
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